Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 1/20 | 0.59 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.57 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.57 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | PPIA | P62937 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1092055 | 0.93 | AVPR2 (0.59) | AVPR2GPR27LMNASMN1; SMN2TSHR | |
| SCHEMBL9974112 | 0.92 | AVPR2 (0.59) | AVPR2GPR27LMNASMN1; SMN2TSHR | |
| SCHEMBL1102029 | 0.90 | LMNA (0.60) | AVPR2GPR27LMNASMN1; SMN2TSHR | |
| SCHEMBL1102127 | 0.90 | LMNA (0.59) | LMNASMN1; SMN2TSHRSCN3APKM | |
| SCHEMBL1102121 | 0.88 | PKM (0.64) | LMNASMN1; SMN2TSHRSCN3APKM | |
| SCHEMBL1102072 | 0.87 | SMN1; SMN2 (0.56) | LMNASMN1; SMN2TSHRSCN3APKM | |
| SCHEMBL9974136 | 0.87 | AVPR2 (0.58) | AVPR2GPR27LMNASMN1; SMN2TSHR | |
| SCHEMBL1102141 | 0.87 | LMNA (0.60) | LMNASMN1; SMN2TSHRSCN3APKM | |
| SCHEMBL1102109 | 0.86 | SCN9A (0.45) | AVPR2GPR27SCN3ASCN5ASCN9A | |
| SCHEMBL9972246 | 0.85 | AVPR2 (0.59) | AVPR2GPR27LMNASMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153655-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153655-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-10 | — | — | US | disclosed |
| US-20100087479-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087479-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-08 | — | — | US | disclosed |
| US-7615563-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-10 | — | — | US | disclosed |
| US-7615563-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087479-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | SCNN1G, KCNN3, KCNN2 | AVPR2 1442/4885GPR27 1810/4885LMNA 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.